{"prompt": "['EudraCT Number 2019-002880-82, IRAS Number 1003208', '3.', 'Biochemical analysis of maternal blood for liver function tests at Follow up 2 (ALT,', 'bilirubin, ALP), bile acids, C reactive protein (including highly sensitive analyses)', '4. Proportion of women requiring insulin treatment (time until treatment and total dose', 'of insulin required)', '5. Maternal gestational weight change at 36 weeks compared to weight at first', 'trimester screening visit.', '6. Measurement of vascular responses at Follow up 1 and 2, including: i) maternal', 'pulse wave velocity (PWV), with systolic and diastolic blood pressure, ii) central', 'arterial pressure (cP), and iii) augmentation index (Alx)', '7. Estimated blood loss at time of delivery.', '- Biomedical and clinical neonatal outcomes at birth:', '1. Mode of birth (rates of caesarean section (CS), (elective & emergency), assisted', 'vaginal birth and spontaneous vaginal delivery (SVD))', '2. Gestational age at birth', '3. Apgar scores @ 5 minutes post birth', '4. Occurrence of shoulder dystocia', '5. Cord blood C-peptide, triglyceride, total cholesterol, calculated LDL-cholesterol,', 'HDL-cholesterol and free fatty acid concentrations', '6.', 'Infant birth weight (customised birth weight percentile51 proportion of babies born', 'large for gestational age (LGA), proportion of babies born small for gestational age', '(SGA)', '7.', 'Neonatal morbidity (treatment for neonatal hypoglycaemia, neonatal jaundice,', 'respiratory distress or birth trauma)', '8. Neonatal intensive care and special care unit admission (duration of hospital stay)', '9. Stillbirth and neonatal death', 'For endpoints of the GUARD MEC sub-study please see section 19. Mechanistic Sub-', 'study: GUARD MEC.', '4.3 Trial Design', 'GUARD is a pilot phase IV two-armed, open label, multi-centre randomised,', 'controlled trial, designed to discover possible new uses for UDCA, a drug commonly used', 'in pregnancy for other conditions.', '158 overweight or obese women with a clinical diagnosis of GDM that requires', 'management with pharmacological intervention will be recruited and randomised to one of', 'two trial interventions in the UK.', 'GUARD protocol V1.0 11Mar20', 'Page 14 of 53']['EudraCT Number 2019-002880-82, IRAS Number 1003208', '4.4 Trial Flowchart', 'Patient pathway', 'Research activity', \"26*0-2816 weeks' gestation: Woman undergo\", 'oral glucose tolerance test (OGTT)', 'J', 'GUARD PIS', 'Positive for GDM', 'Negative for GDM', 'GUARD MEC PIS', 'J', \"2710-29\u00b06 weeks' gestation.\", 'Referred to GDM clinic for dietary advice and', 'Contacted prior to', 'glucose monitoring', 'appointment for brief', 'discussion regarding glucose', 'J', 'control', \"weeks' gestation\", 'I', 'J', 'J', 'Seen by study team member.', 'Dietary glucose', 'Has opportunity and time to', 'Dietary glucose', 'control GOOD:', 'control POOR', 'discuss study in detail', 'routine clinical', 'J', 'care pathway', 'Ask to consider', 'I', 'GUARD', 'Ask to consider', 'GUARD MEC', 'No', 'Yes', 'I', 'Ask to consider GUARD MEC', 'Yes', 'No', 'Consent,', 'I', 'screen,', 'No', 'Yes', 'Normal care', 'Consent, screen,', 'baseline data,', 'J', 'baseline data and', 'pathway', 'randomise', 'arrange for', 'Consent,', 'GUARD MEC visit', 'screen,', 'baseline data', 'Metformin', 'UDCA', 'and arrange', 'for GUARD', \"MEC visit'\", '+', 'GUARD MEC at Week', \"Seen in GDM and antenatal clinics at 32 and 36 week's\", '36: breakfast & research', 'gestation: Clinical and research appointments', 'blood samples', 'Pregnancy and labour outcome data including', 'neonatal anthropometry and cord blood samples', '6-12 weeks post-natal', 'HbA1C results obtained from primary care', 'GUARD protocol V1.0 11Mar20', 'Page 15 of 53']\n\n###\n\n", "completion": "END"}